Qureight
Year2024
RoundSeries A
Amount$8.5M
Overall
Summary
11 slides
11 slides
1 slide
Data curation to accelerate drug development.
1 slide
Qureight accelerates clinical trial development through data curation and AI to bring better therapies to patients with high unmet needs.
1 slide
Our customers, including AstraZeneca and Vicore, use us to support billion dollar decisions, pushing boundaries in respiratory disease research.
1 slide
Clinical trial data analysis is broken, risking failed drugs and huge financial losses, as evidenced by Roche's failed $1.4Bn investment and $200M trial loss.
2 slides
Qureight offers a single platform to streamline clinical trial data, enabling faster, more accurate drug development decisions by consolidating and analyzing data with AI.
1 slide
Our key products include AI image analysis, virtual trial arms, and Central Read System, all designed to enhance clinical trial efficiency and decision-making.
1 slide
The competitive landscape is fragmented, with CROs, Pharma, and Med tech AI struggling with siloed data, lack of real-world datasets, and technological limitations.
1 slide
The global lung and heart clinical trials market is projected to grow significantly, with Qureight positioned to capitalize on over 3200 trials per year.
1 slide
Our leadership is a unique blend of clinicians and software engineers, providing expertise in both healthcare and technology.
1 slide
We are raising $7.5M to enhance our imaging and data integration, expand our data lake, and support increased clinical trials, driving growth.
